Dianthus Therapeutics, Inc. /DE/ (DNTH) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$101.12

From 52W high−16.51%

Volume2.80M

Market cap$5.42B

P/E (TTM)—

P/S (TTM)2844.0x

Div yield—

Key dataSep 18, 2026

Open

$101.12

From 52W high

−16.51%

Volume

2.80M

Market cap

$5.42B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−153.5x

P/E (TTM)

—

RSI (14)

36.6

MomentumView details →

1D Return

−4.26%

YTD Return

+138.75%

SummaryUpdated Jun 1, 2026

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is a clinical-stage biotechnology company founded in 2015 and headquartered in New York, New York. The company went public in June 2018 and focuses on developing novel monoclonal antibody treatments for patients suffering from severe autoimmune and inflammatory diseases. Dianthus is currently advancing its lead drug candidate, DNTH103, through Phase 1 clinical trials for multiple neurological conditions including generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

Ask drillr about Dianthus Therapeutics, Inc. /DE/ →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−153.5x

EV/Sales

2378.9x

P/S (TTM)

2844.0x

P/B (TTM)

4.6x

ProfitabilityView details →

Gross Margin

96.01%

Net Margin

−1570.85%

EBITDA Margin

−1549.89%

ROE (TTM)

−2.55%

ROA (TTM)

−2.47%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−60.77%

EPS YoY

+96.00%

FCF YoY

−55.15%

Revenue CAGR 3Y

−31.80%

EPS CAGR 3Y

−64.71%

EBITDA YoY

+75.92%

MomentumView details →

1D Return

−4.26%

YTD Return

+138.75%

1Y Return

+167.73%

RSI (14)

36.6

vs 50D SMA

−7.91%

vs 200D SMA

+24.90%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

26.10x

Quick Ratio

26.10x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.90

EPS Surprise

−6.35%

Beats (12Q)

4/12

Next Q EPS Est

−$0.94

Avg Surprise (4Q)

−8.49%

Rev Surprise

156.07%

Financials snapshotView financials →

Revenue (TTM)

1.90M

Net Income (TTM)

−29.91M

Op. CF (TTM)

−155.38M

Next earningsNov 5, 2026 →

Latest newsMore news →

Dianthus Therapeutics is advancing DNTH312, a first-in-class bifunctional fusion protein, aiming to be Phase 1 ready by year-end 2027.47d ago

Dianthus Therapeutics is advancing DNTH212 for Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis, with Phase 1 healthy volunteer data anticipated by year-end 2026.47d ago

Similar companies

PTC Therapeutics, Inc.PTCT Cogent Biosciences, Inc.COGT CRISPR Therapeutics AGCRSP CK Life Sciences Int'l., (Holdings) Inc.00775.HK Apellis Pharmaceuticals, Inc.APLS 博拓生物688767.SH Find similar companies →

Latest newsMore news →

Dianthus Therapeutics is advancing DNTH312, a first-in-class bifunctional fusion protein, aiming to be Phase 1 ready by year-end 2027.47d ago Dianthus Therapeutics is advancing DNTH212 for Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis, with Phase 1 healthy volunteer data anticipated by year-end 2026.47d ago